Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in High-risk Patients With Acute Non-disabling Cerebrovascular Events (ADANCE): Rationale, Objectives, and Design

NCT01924325 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT01924325
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01924325 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Apixaban Versus Dual-antiplatelet Therapy (Clopidogrel and Aspirin) in High-risk Patients With Acute Non-disabling Cerebrovascular Events (ADANCE): Rationale, Objectives, and Design
Lead sponsor
Xijing Hospital
Phase
Phase 2/3
Overall status
Unknown status
Start date
January 31, 2014
Completion date
July 31, 2016
Enrollment
10,000 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

ischemic stroke, tia